Full-Time

Senior Manager

Data Science, Forecasting

Updated on 9/12/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

No salary listed

Hyderabad, Telangana, India

In Person

Category
Data & Analytics (1)
Required Skills
LLM
Scikit-learn
MLOps
Redshift
Python
Airflow
Data Visualization
Data Science
TensorFlow
R
Forecasting
PyTorch
Apache Spark
SQL
Machine Learning
Kinesis
MLflow
A/B Testing
RAG
AWS
Risk Management

Get referred to Amgen

See people who can refer or advise you

Requirements
  • The candidate must have 15 or more years of professional experience delivering data science, machine learning, forecasting, artificial intelligence, analytics, or decision-support solutions that created measurable business value.
  • The candidate must have 7 or more years of experience managing, leading, or formally developing data science, machine learning, artificial intelligence, analytics, or cross-functional technical teams.
  • The candidate must have experience setting data science strategy, prioritizing a portfolio of work, managing stakeholder expectations, and leading teams through ambiguous, high-impact business problems.
  • The candidate must have deep experience with forecasting, predictive modeling, statistical modeling, probabilistic or Bayesian methods, uncertainty quantification, scenario analysis, experimentation, or optimization.
  • The candidate must have experience partnering with machine learning engineering, software engineering, product, program, or platform teams to move models and analytics capabilities from prototype into production or scaled business use.
  • The candidate must have experience with modern artificial intelligence systems, including large language model-powered applications, artificial intelligence agents, retrieval or information-retrieval systems, evaluation frameworks, guardrails, and human-in-the-loop operating patterns.
  • The candidate must have strong analytical and technical fluency with Python, R, SQL, or equivalent tools, and familiarity with modern data science and machine learning frameworks such as scikit-learn, PyTorch, TensorFlow/JAX, Spark, MLflow, Airflow/Prefect/Dagster, or equivalent technologies.
  • The candidate must be familiar with cloud platforms, enterprise data platforms, model deployment patterns, machine learning operations, model monitoring, reproducibility, governance, security, privacy, and responsible artificial intelligence practices.
  • The candidate must have strong communication and executive-influence skills, including the ability to explain complex methods, forecast uncertainty, assumptions, model risks, and business implications to technical and non-technical audiences.
  • The candidate must demonstrate the ability to hire, coach, mentor, and grow technical talent while fostering collaboration, inclusion, accountability, and a high bar for scientific and delivery excellence.
Responsibilities
  • Lead, coach, and develop a team of data scientists, artificial intelligence and machine learning scientists, and analytics professionals by establishing priorities, standards, career development plans, and an inclusive, accountable team culture.
  • Define and own the data science roadmap for enterprise forecasting, simulation, scenario planning, uncertainty quantification, predictive analytics, large language model-enabled applications, and artificial intelligence-assisted decision support aligned to business priorities.
  • Partner with senior business, product, program, operations, commercial, manufacturing, supply chain, finance, engineering, and artificial intelligence stakeholders to translate ambiguous planning and decision challenges into prioritized data science initiatives with clear outcomes and measurable value.
  • Establish standards for forecast quality, model validation, experimentation, evaluation frameworks, guardrails, explainability, auditability, reproducibility, model monitoring, drift detection, and responsible artificial intelligence practices in high-impact and regulated business contexts.
  • Create and maintain measurement frameworks to evaluate forecast accuracy, uncertainty calibration, decision quality, operational efficiency, reliability, user adoption, and business impact, and lead build-measure-learn cycles that improve solutions based on real-world performance.
  • Serve as a senior advisor to stakeholders by communicating forecasts, uncertainty, model assumptions, trade-offs, risks, and recommendations to technical and executive audiences.
  • Manage the team portfolio, roadmap trade-offs, resourcing, stakeholder expectations, delivery risks, and dependencies across data science, engineering, product, and business teams.
  • Identify reusable methods, patterns, platforms, and governance practices that accelerate forecasting and artificial intelligence decision-support delivery and reduce duplication across teams.
  • Research and evaluate emerging open-source, vendor, and internal tools related to forecasting, decision intelligence, large language models, artificial intelligence agents, machine learning operations, model evaluation, and artificial intelligence governance for potential business application.
  • Promote data science practices including scientific rigor, code quality, documentation, peer review, reproducibility, ethical artificial intelligence use, operational excellence, and collaboration with engineering and business partners.
Desired Qualifications
  • Experience leading forecasting, demand planning, commercial analytics, supply chain, manufacturing, operations, or decision intelligence teams in biotechnology, pharmaceuticals, healthcare, retail, consumer goods, or other complex regulated or operational environments.
  • Knowledge of healthcare commercial concepts such as payer/provider dynamics, formulary access, coverage, patient access, channel dynamics, epidemiology, product lifecycle considerations, or launch planning.
  • Experience building or leading teams that delivered production machine learning or artificial intelligence products, internal decision-support tools, dashboards, workflow applications, or autonomous or semi-autonomous artificial intelligence capabilities used by non-technical stakeholders.
  • Experience with artificial intelligence agent architectures, multi-system orchestration, tool or function calling, retrieval-augmented generation, MCP or similar integration patterns, and large language model evaluation or serving approaches in production or enterprise settings.
  • Experience designing guardrails, model or agent evaluation suites, A/B tests, offline and online metrics, auditability, explainability, fairness, risk management, and governance controls for high-impact artificial intelligence or machine learning systems.
  • Experience using Amazon Web Services or equivalent cloud services such as S3, Redshift, SageMaker, EMR, Kinesis, Lambda, EC2, EKS/ECS, or comparable Google Cloud or Azure services.
  • Experience managing roadmaps, budget and resource trade-offs, vendor or platform partnerships, stakeholder governance forums, or communities of practice for data science or artificial intelligence delivery.
  • A track record of influencing senior leaders, shaping enterprise artificial intelligence and data science standards, and scaling reusable approaches across multiple products, functions, or business domains.
  • Publications, patents, conference presentations, open-source contributions, or other evidence of thought leadership in data science, forecasting, artificial intelligence systems, large language models, machine learning operations, or decision intelligence.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 10% to $10.1 billion, and guidance increased to $38.2 billion-$39.4 billion.
  • Repatha sales jumped 37% to $953 million in Q2 2026, with U.S. prescriptions up 50%.
  • MariTide advanced through multiple Phase 3 studies in 2026, supporting a 2027 obesity catalyst.

What critics are saying

  • Prolia sales fell 32% in Q2 2026 as biosimilars attack Amgen’s legacy cash cow.
  • FDA proposed withdrawing Tavneos in April 2026, signaling regulatory risk from integrity and efficacy issues.
  • Olpasiran now faces Novartis pelacarsen failure scrutiny; a negative 2028 OCEAN(a) readout would crush Lp(a) upside.

What makes Amgen unique

  • Repatha, Evenity, and Uplizna diversify Amgen beyond one blockbuster, per August 2026 sales.
  • MariTide targets quarterly or eight-week dosing, unlike Lilly and Novo Nordisk weekly injections.
  • Amgen’s 2027 Hyderabad Science and Innovation Center expands AI-enabled drug discovery globally.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Sep 10th, 2026
Amgen trades at 17x 2026 earnings, but forecast margin expansion assumes MariTide success

Amgen trades at $393 per share, representing a trailing multiple of 23.3 times adjusted earnings. The biotech faces declining sales from Prolia and XGEVA, down 33% year-over-year to $1.1 billion in Q2 2026, due to biosimilar competition. Six key growth medicines grew 26% year-over-year, accounting for nearly 70% of Q2 product sales. Analysts forecast the forward multiple at 17.0 times for fiscal 2026 and 16.1 times for 2027. However, consensus assumes expanding profit margins whilst Amgen increases spending. Non-GAAP research spending is set to grow in high single digits for 2026, funding nine Phase III trials for MariTide, its obesity treatment candidate. Management warned of meaningful operating expense increases in Q3 2026. The valuation depends on margin expansion materialising during this investment phase.

Yahoo Finance
Sep 7th, 2026
Amgen's $437 olpasiran bet faces higher bar after Novartis Lp(a) drug fails Phase 3 trial

Amgen faces heightened scrutiny for its experimental heart drug olpasiran after rival Novartis's pelacarsen failed to reduce major cardiovascular events in a Phase 3 trial, despite successfully lowering lipoprotein(a) levels. The setback demonstrates that improving laboratory biomarkers may not translate to better patient outcomes. Amgen's OCEAN(a) outcomes study has enrolled 7,297 participants and is tracking heart-related deaths and procedures over roughly five years. While olpasiran uses a different design and may target different patients, pelacarsen's failure removes assumptions about the commercial value of lowering Lp(a). Amgen's shares traded at $437.23, sitting 19.54% above its estimated fair value of $365.76. The company reported $10.1 billion in second-quarter revenue and $3.5 billion in free cash flow.

Yahoo Finance
Sep 1st, 2026
Amgen's Repatha hits $953M in Q2 sales, up 37% as Cramer calls it "biggest market of all time

Jim Cramer highlighted Amgen's cholesterol drug Repatha as a key driver behind the company's 31% year-to-date rally, calling it an overlooked catalyst by Wall Street. The injectable treatment, administered every two weeks, reduces death risk by 20% in patients at high risk for heart attack or stroke. Repatha generated $953 million in second-quarter sales, up 37% year-over-year. US new prescriptions surged over 50%, split evenly between cardiologist use and primary-care adoption for high-risk patients. Cramer noted the drug works against diabetes and high cholesterol, though insurance reimbursement has posed challenges. Amgen trades at a forward PE of 19, compared to Eli Lilly's 32, whilst outperforming Lilly's 10% gain this year. Repatha is one of six growth drivers representing nearly 70% of Amgen's product sales. The company raised full-year revenue guidance to $38.2-$39.4 billion.

Yahoo Finance
Aug 19th, 2026
Amgen surges 3.5% to $440 as healthcare stocks hit record high on strong Q2 results

Amgen shares jumped 3.5% to $440.08 on Wednesday as healthcare stocks reached record highs. The biotech company reported second-quarter revenue of $10.1 billion, up 10%, whilst GAAP earnings surged 65% to $4.37 per share. Twenty-two of Amgen's medicines posted double-digit sales growth, with seventeen products generating over $1 billion in annualised sales. Six key growth products climbed 26% and now account for nearly 70% of product revenue. The rally came as investors rotated into healthcare following excitement around Merck and Moderna's melanoma breakthrough. However, Amgen now trades at a 19% premium to its fair value estimate of $365.04, putting pressure on execution as some products like Prolia face headwinds.

Yahoo Finance
Aug 14th, 2026
Amgen and Regeneron emerge as GLP-1 investment alternatives beyond Eli Lilly and Novo Nordisk

Amgen and Regeneron could benefit from surging demand for GLP-1 drugs, which traditionally treated diabetes but now address obesity and obstructive sleep apnea. Amgen's stock is up 27% this year, with second-quarter revenue rising 10% year-over-year to $10.1 billion. The company is testing MariTide, an investigational GLP-1 medicine, in phase 3 studies for weight management and diabetes. MariTide could be administered monthly or less frequently, offering a convenience advantage over current daily or weekly treatments. Regeneron is also positioned to capitalise on the GLP-1 market expansion. Both companies present alternatives to current market leaders Eli Lilly and Novo Nordisk for investors seeking exposure to the growing GLP-1 drug category.